Información del artículo
Abstract
Objective
To establish recommendations for using and interpreting magnetic resonance imaging (MRI) results in the diagnosis and follow up of multiple sclerosis (MS).
MethodBased on an extensive review of the literature and on their own experience, an expert group on MS produced a consensus on recommendations for using and interpreting MRI results in MS diagnosis and follow up.
ResultsA brain MRI must be performed whenever possible in the initial diagnosis and assessment of patients suspected with MS. A spinal MRI study should be performed on all patients whose clinical onset shows signs of spinal cord syndrome, when the brain MRI findings are not very specific or when the brain MRI is normal in patients diagnosed clinically with MS. Cranial studies should be performed using appropriate repositioning techniques and different MR sequences, such as proton-density and T2-weighted fast spin-echo, and Fast-FLAIR. The use of contrast is mandatory whenever attempting to determine the temporal and spatial dissemination of demyelinating lesions for the initial diagnosis, or to determine inflammatory activity or lesion progression in follow-up studies.
ConclusionsThe use of recommendations for using and interpreting MRI results in MS diagnosis and follow up should help to rationalise resources and optimise the clinical results arising from its practice.
Keywords:
Multiple sclerosis
Magnetic resonance imaging
Recommendations
Resumen
Objetivo
Establecer unas recomendaciones para utilizar e interpretar la resonancia magnética (RM) en el diagnóstico y el seguimiento de la esclerosis múltiple (EM).
MétodoBasados en una extensa revisión de la literatura y en su propia experiencia personal, un grupo de expertos en EM consensuaron unas recomendaciones con este objetivo.
ResultadosSiempre que sea posible se debe practicar un estudio de RM craneal en el diagnóstico o la evaluación inicial de los pacientes con sospecha de EM. Un estudio de RM espinal debe realizarse en todo paciente cuyo inicio clínico es un síndrome medular, cuando los hallazgos de la RM cerebral sean poco específicos o cuando el estudio de RM cerebral sea normal en pacientes diagnosticados clínicamente de EM. Los estudios cerebrales deben efectuarse con técnicas de reposicionamiento adecuadas y combinando secuencias ponderadas en densidad protónica, T2 y fast-FLAIR. Es obligado utilizar contraste siempre que se pretenda determinar diseminación temporal o espacial de las lesiones desmielinizantes para el diagnóstico inicial, o para determinar actividad inflamatoria o progresión lesional en los estudios de seguimiento.
ConclusionesDisponer de unas recomendaciones para la utilización y la interpretación de los estudios de RM en el diagnóstico y el seguimiento de los pacientes con EM debe servir para racionalizar los recursos y para optimizar los resultados clínicos derivados de su práctica.
Palabras clave:
Esclerosis múltiple
Resonancia magnética
Recomendaciones
El Texto completo está disponible en PDF
References
[1.]
F. Fazekas, F. Barkhof, M. Filippi, et al.
The contribution of magnetic resonance imaging to the diagnosis of multiple sclerosis.
Neurology, 53 (1999), pp. 448-457
[2.]
P.A. Brex, O. Ciccarelli, J.I. O’Riordan, M. Sailer, A.J. Thompson, D.H. Miller.
A longitudinal study of abnormalities on MRI and disability from multiple sclerosis.
N Engl J Med, 346 (2002), pp. 158-164
[3.]
L. Kappos, C.H. Polman, M.S. Freedman, et al.
Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes.
Neurology, 67 (2006), pp. 1242-1249
[4.]
D.H. Miller, P. Runge, G. Johnson, et al.
Serial gadolinium enhanced magnetic resonance imaging in multiple sclerosis.
Brain, 111 (1988), pp. 927-939
[5.]
M. Filippi, V. Dousset, H.F. McFarland, D.H. Miller, R.I. Grossman.
Role of magnetic resonance imaging in the diagnosis and monitoring of multiple sclerosis: consensus report of the White Matter Study Group.
J Magn Reson Imaging, 15 (2002), pp. 499-504
[6.]
W.I. McDonald, A. Compston, G. Edan, et al.
Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis.
Ann Neurol, 50 (2001), pp. 121-127
[7.]
M. Filippi, M.A. Horsfield, H.J. Ader, et al.
Guidelines for using quantitative measures of brain magnetic resonance imaging abnormalities in monitoring the treatment of multiple sclerosis.
Ann Neurol, 43 (1998), pp. 499-506
[8.]
D.H. Miller, R.I. Grossman, S.C. Reingold, H.F. McFarland.
The role of magnetic resonance techniques in understanding and managing multiple sclerosis.
Brain, 121 (1998), pp. 3-24
[9.]
D.H. Miller, F. Barkhof, J.J. Nauta.
Gadolinium enhancement increases the sensitivity of MRI in detecting disease activity in multiple sclerosis.
Brain, 116 (1993), pp. 1077-1094
[10.]
M.A. Rocca, S.J. Hickman, L. Bö, F. Agosta, D.H. Miller, G. Comi, et al.
Imaging the optic nerve in multiple sclerosis.
Mult Scler, 11 (2005), pp. 537-541
[11.]
J.W. Thorpe, D. Kidd, I.F. Moseley, et al.
Spinal MRI in patients with suspected multiple sclerosis and negative brain MRI.
Brain, 119 (1996), pp. 709-714
[12.]
J.C. Bot, F. Barkhof, G. Lycklama à Nijeholt, et al.
Differentiation of multiple sclerosis from other inflammatory disorders and cerebrovascular disease: value of spinal MR imaging.
Radiology, 223 (2002), pp. 46-56
[13.]
A.J. Thompson, X. Montalban, F. Barkhof, et al.
Diagnostic criteria for primary progressive multiple sclerosis: a position paper.
Ann Neurol, 47 (2000), pp. 831-835
[14.]
C.H. Polman, S.C. Reingold, G. Edan, M. Filippi, H.P. Hartung, L. Kappos, et al.
Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”.
Ann Neurol, 58 (2005), pp. 840-846
[15.]
W.B. Patola, B.A. Coulter, P.M. Chipperfield, S.S. Lingawi.
A comparison of conventional spin-echo and fast spin-echo in the detection of multiple sclerosis.
J Magn Reson Imaging, 13 (2001), pp. 657-667
[16.]
R.H. Hashemi, W.G. Bradley, D.Y. Chen, et al.
Suspected multiple sclerosis: MR imaging with a thin-section fast FLAIR pulse sequence.
Radiology, 196 (1995), pp. 505-510
[17.]
M.L. Gawne-Cain, J.I. O’Riordan, A.J. Thompson, I.F. Moseley, D.H. Miller.
Multiple sclerosis lesion detection in the brain: a comparison of fast fluid-attenuated inversion recovery and conventional T2-weighted dual spin echo.
Neurology, 49 (1997), pp. 364-370
[18.]
T.A. Yousry, M. Filippi, C. Becker, M.A. Horsfield, R. Voltz.
Comparison of MR pulse sequences in the detection of multiple sclerosis lesions.
AJNR Am J Neuroradiol, 18 (1997), pp. 959-963
[19.]
G.J. Lycklama à Nijeholt, J.A. Castelijns, J. Weerets, M.R. Sagittal, et al.
of multiple sclerosis in the spinal cord: fast versus conventional spin-echo imaging.
Am J Neuroradiol, 19 (1998), pp. 355-360
[20.]
G. Lycklama, A. Thompson, M. Filippi, et al.
Spinal-cord MRI in multiple sclerosis.
Lancet Neurol, 2 (2003), pp. 555-562
[21.]
D. Kidd, J.W. Thorpe, A.J. Thompson, et al.
Spinal cord MRI using multi-array coils and fast spin echo. II. Findings in multiple sclerosis.
Neurology, 43 (1993), pp. 2632-2637
[22.]
P.D. Molyneux, N. Tubridy, G.J. Parker, et al.
The effect of section thickness on MR lesion detection and quantification in multiple sclerosis.
AJNR Am J Neuroradiol, 19 (1998), pp. 1715-1720
[23.]
M.L. Gawne-Cain, S. Webb, P. Tofts, D.H. Miller.
Lesion volume measurement in multiple sclerosis: how important is accurate repositioning?.
J Magn Reson Imaging, 6 (1996), pp. 705-713
[24.]
H.L. Gallagher, D.G. MacManus, S.L. Webb, D.H. Miller.
A reproducible repositioning method for serial magnetic resonance imaging studies of the brain in treatment trials for multiple sclerosis.
J Magn Reson Imaging, 7 (1997), pp. 439-441
[25.]
M. Filippi, N. Marciano, R. Capra, et al.
The effect of imprecise repositioning on lesion volume measurements in patients with multiple sclerosis.
Neurology, 49 (1997), pp. 274-276
[26.]
I.L. Tan, R.A. Van Schijndel, F. Fazekas, et al.
Image registration and subtraction to detect active T(2) lesions in MS: an interobserver study.
J Neurol, 249 (2002), pp. 767-773
[27.]
J.C. Masdeu, C. Quinto, C. Olivera, M. Tenner, D. Leslie, P. Visintainer.
Open-ring imaging sign: highly specific for atypical brain demyelination.
Neurology, 54 (2000), pp. 1427-1433
[28.]
F. Cotton, H.L. Weiner, F.A. Jolesz, C.R. Guttmann.
MRI contrast uptake in new lesions in relapsing-remitting MS followed at weekly intervals.
Neurology, 60 (2003), pp. 640-646
[29.]
F. Barkhof, M. Filippi, J.H. Van Waesberghe, et al.
Improving interobserver variation in reporting gadolinium-enhanced MRI lesions in multiple sclerosis.
Neurology, 49 (1997), pp. 1682-1688
[30.]
V. Janardhan, S. Suri, R. Bakshi.
Multiple sclerosis: hyperintense lesions in the brain on nonenhanced T1-weighted MR images evidenced as areas of T1 shortening.
Radiology, 244 (2007), pp. 823-831
[31.]
M. Filippi, T. Yousry, A. Campi, et al.
Comparison of triple dose versus standard dose gadolinium-DTPA for detection of MRI enhancing lesions in patients with MS.
Neurology, 46 (1996), pp. 379-384
[32.]
V.P. Mathews, K.S. Caldemeyer, J.L. Ulmer, H. Nguyen, W.T. Yuh.
Effects of contrast dose, delayed imaging, and magnetization transfer saturation on gadolinium-enhanced MR imaging of brain lesions.
J Magn Reson Imaging, 7 (1997), pp. 14-22
[33.]
F. Sardanelli, A. Iozzelli, C. Losacco, A. Murialdo, M. Filippi.
Three subsequent single doses of gadolinium chelate for brain MR imaging in multiple sclerosis.
AJNR Am J Neuroradiol, 24 (2003), pp. 658-662
[34.]
D.R. Broome.
Nephrogenic systemic fibrosis associated with gadolinium based contrast agents: a summary of the medical literature reporting.
Eur J Radiol, 66 (2008), pp. 230-234
[35.]
M.A. Van Walderveen, F. Barkhof, O.R. Hommes, et al.
Correlating MRI and clinical disease activity in multiple sclerosis: relevance of hypointense lesions on short-TR/short-TE (T1-weighted) spin-echo images.
Neurology, 45 (1995), pp. 1684-1690
[36.]
P.D. Molyneux, D.H. Miller, M. Filippi, et al.
Visual analysis of serial T2-weighted MRI in multiple sclerosis: intra- and interobserver reproducibility.
Neuroradiology, 41 (1999), pp. 882-888
[37.]
CHAMPS Study Group.
MRI predictors of early conversion to clinically definite MS in the CHAMPS placebo group.
Neurology, 59 (2002), pp. 998-1005
[38.]
F. Barkhof, M. Filippi, D.H. Miller, et al.
Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis.
Brain, 120 (1997), pp. 2059-2069
[39.]
A.L. Horowitz, R.D. Kaplan, G. Grewe, R.T. White, L.M. Salberg.
The ovoid lesion: a new MR observation in patients with multiple sclerosis.
AJNR Am J Neuroradiol, 10 (1989), pp. 303-305
[40.]
A. Bitsch, T. Kuhlmann, C. Stadelmann, H. Lassmann, C. Lucchinetti, W. Bruck.
A longitudinal MRI study of histopathologically defined hypointense multiple sclerosis lesions.
Ann Neurol, 49 (2001), pp. 793-796
[41.]
A. Gass, M. Filippi, M.E. Rodegher, A. Schwartz, G. Comi, M.G. Hennerici.
Characteristics of chronic MS lesions in the cerebrum, brainstem, spinal cord, and optic nerve on T1-weighted MRI.
Neurology, 50 (1998), pp. 548-550
[42.]
A. Seewann, H. Vrenken, P. Van der Valk, et al.
Diffusely abnormal white matter in chronic multiple sclerosis: imaging and histopathologic analysis.
Arch Neurol, 66 (2009), pp. 601-609
[43.]
B.J. Bedell, P.A. Narayana.
Implementation and evaluation of a new pulse sequence for rapid acquisition of double inversion recovery images for simultaneous suppression of white matter and CSF.
J Magn Reson Imaging, 8 (1998), pp. 544-547
[44.]
J.J. Geurts, P.J. Pouwels, B.M. Uitdehaag, C.H. Polman, F. Barkhof, J.A. Castelijns.
Intracortical lesions in multiple sclerosis: improved detection with 3D double inversion-recovery MR imaging.
Radiology, 236 (2005), pp. 254-260
[45.]
M.K. Erskine, L.L. Cook, K.E. Riddle, J.R. Mitchell, S.J. Karlik.
Resolution-dependent estimates of multiple sclerosis lesion loads.
Can J Neurol Sci, 32 (2005), pp. 205-212
[46.]
N.L. Sicotte, R.R. Voskuhl, S. Bouvier, R. Klutch, M.S. Cohen, J.C. Mazziotta.
Comparison of multiple sclerosis lesions at 1.5 and 3.0 Tesla.
Invest Radiol, 38 (2003), pp. 423-427
[47.]
M.P. Wattjes, M. Harzheim, C.K. Kuhl, et al.
Does high-field MR imaging have an influence on the classification of patients with clinically isolated syndromes according to current diagnostic MR imaging criteria for multiple sclerosis?.
AJNR Am J Neuroradiol, 27 (2006), pp. 1794-1798
[48.]
B.L. Schmitz, A.J. Aschoff, M.H. Hoffmann, G. Grön.
Advantages and pitfalls in 3T MR brain imaging: a pictorial review.
AJNR Am J Neuroradiol, 26 (2005), pp. 2229-2237
[49.]
D.H. Miller.
Biomarkers and surrogate outcomes in neurodegenerative disease: lessons from multiple sclerosis.
NeuroRx, 1 (2004), pp. 284-294
[50.]
R. Bakshi, A. Minagar, Z. Jaisani, J.S. Wolinsky.
Imaging of multiple sclerosis: role in neurotherapeutics.
NeuroRx, 2 (2005), pp. 277-303
[51.]
R. Zivadinov, M. Stosic, J.L. Cox, D.P. Ramasamy, M.G. Dwyer.
The place of conventional MRI and newly emerging MRI techniques in monitoring different aspects of treatment outcome.
J Neurol, 255 (2008), pp. 61-74
[52.]
M. Law, D.E. Meltzer, S. Cha.
Spectroscopic magnetic resonance imaging of a tumefactive demyelinating lesion.
Neuroradiology, 44 (2002), pp. 986-989
[53.]
T. Ernst, L. Chang, I. Walot, K. Huff.
Physiologic MRI of a tumefactive multiple sclerosis lesion.
Neurology, 51 (1998), pp. 1486-1488
[54.]
N. De Stefano, Z. Caramanos, M.C. Preul, G. Francis, J.P. Antel, D.L. Arnold.
In vivo differentiation of astrocytic brain tumors and isolated demyelinating lesions of the type seen in multiple sclerosis using 1H magnetic resonance spectroscopic imaging.
Ann Neurol, 44 (1998), pp. 273-278
[55.]
N. De Stefano, M.L. Bartolozzi, L. Guidi, M.L. Stromillo, A. Federico.
Magnetic resonance spectroscopy as a measure of brain damage in multiple sclerosis.
J Neurol Sci, 233 (2005), pp. 203-208
[56.]
C. Majós, C. Aguilera, J. Alonso, et al.
Proton MR spectroscopy improves discrimination between tumor and pseudotumoral lesion in solid brain masses.
AJNR Am J Neuroradiol, 30 (2009), pp. 544-551
[57.]
N. De Stefano, M. Filippi, D. Miller, et al.
Guidelines for using proton MR spectroscopy in multicenter clinical MS studies.
Neurology, 69 (2007), pp. 1942-1952
[58.]
J.H. Simon.
Brain atrophy in multiple sclerosis: what we know and would like to know.
Mult Scler, 12 (2006), pp. 679-687
[59.]
R.A. Bermel, R. Bakshi.
The measurement and clinical relevance of brain atrophy in multiple sclerosis.
Lancet Neurol, 5 (2006), pp. 158-170
[60.]
E. Fisher, J.C. Lee, K. Nakamura, R.A. Rudick.
Gray matter atrophy in multiple sclerosis: a longitudinal study.
Ann Neurol, 64 (2008), pp. 255-265
[61.]
R.A. Rudick, J.C. Lee, K. Nakamura, E. Fisher.
Gray matter atrophy correlates with MS disability progression measured with MSFC but not EDSS.
J Neurol Sci, 282 (2009),
[62.]
D.T. Chard, C.M. Griffin, G.J. Parker, et al.
Brain atrophy in clinically early relapsing-remitting multiple sclerosis.
Brain, 125 (2002), pp. 327-337
[63.]
R.A. Rudick, E. Fisher, J.C. Lee, J. Simon, L. Jacobs, Multiple Sclerosis Collaborative Research Group.
use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS.
Neurology, 53 (1999), pp. 1698-1704
[64.]
D.H. Miller, F. Barkhof, J.A. Frank, G.J. Parker, A.J. Thompson.
Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance.
Brain, 125 (2002), pp. 1676-1695
[65.]
N.A. Losseff, S.L. Webb, J.I. O’Riordan, et al.
Spinal cord atrophy and disability in multiple sclerosis. A new reproducible and sensitive MRI method with potential to monitor disease progression.
Brain, 119 (1996), pp. 701-708
[66.]
A. Rovira, J. Alonso, G. Cucurella, et al.
Evolution of multiple sclerosis lesions on serial contrast-enhanced T1-weighted and magnetization-transfer MR images.
AJNR Am J Neuroradiol, 20 (1999), pp. 1939-1945
[67.]
M.A. Horsfield.
Magnetization transfer imaging in multiple sclerosis.
J Neuroimaging, 15 (2005), pp. 58S-67S
[68.]
C. Oreja-Guevara, A. Charyl, D. Caputo, R. Cavarretta, M.P. Sormani, M. Filippi.
Magnetization transfer magnetic resonance imaging and clinical changes in patients with relapsing-remitting multiple sclerosis.
Arch Neurol, 63 (2006), pp. 736-740
[69.]
J.T. Chen, D.L. Collins, H.L. Atkins, et al.
Magnetization transfer ratio evolution with demyelination and remyelination in multiple sclerosis lesions.
Ann Neurol, 63 (2008), pp. 254-262
[70.]
P.S. Giacomini, I.R. Levesque, L. Ribeiro, et al.
Measuring demyelination and remyelination in acute multiple sclerosis lesion voxels.
Arch Neurol, 66 (2009), pp. 375-381
[71.]
M. Rovaris, A. Gass, R. Bammer, et al.
Diffusion MRI in multiple sclerosis.
Neurology, 65 (2005), pp. 1526-1532
[72.]
C. Oreja-Guevara, M. Rovaris, G. Iannucci, P. Valvasina, D. Caputo, R. Cavarretta, et al.
Progressive grey matter damage in patients with relapsing-remitting MS: A longitudinal diffusion tensor MRI study.
Arch Neurol, 62 (2005), pp. 578-584
[73.]
J. Renoux, D. Facon, P. Fillard, et al.
MR diffusion tensor imaging and fiber tracking in inflammatory diseases of the spinal cord.
AJNR Am J Neuroradiol, 27 (2006), pp. 1947-1951
[74.]
P. Pantano, C. Mainero, F. Caramia.
Functional brain reorganization in multiple sclerosis: evidence from fMRI studies.
J Neuroimaging, 16 (2006), pp. 104-114
Copyright © 2010. Sociedad Española de Neurología
